PPAR signaling pathway was indicated to be a potential predictor of neoadjuvant chemotherapy response in breast cancer.[29] While numerous studies have demonstrated that targeting focal adhesion kinase could improve trastuzumab response and might be an effective measure to overcome trastuzumab resistance in HER-2 positive breast cancer.[30,31] In addition to these, AMPK was found dysfunctional in breast cancer, with the reduced signaling via the AMPK pathway was correlated with a higher histological grade and axillary node metastasis of breast cancer.[32]. Here, ERBB2 is linked to breast cancer.